key: cord-0287852-5uxbv89r authors: GV, C.; Srikantam, A. title: Comparative quantitative analysis of SARS-CoV-2 Spike neutralizing antibody titers following two anti COVID-19 vaccines in India date: 2021-09-05 journal: nan DOI: 10.1101/2021.08.28.21262753 sha: 6f6e8e3a95fbb056cddb4c94859e68e981364452 doc_id: 287852 cord_uid: 5uxbv89r In COVID 19 pandemic, first line of defense is effective vaccination program. Because of multiple platforms available for vaccine production we tested relative immunogenicity of two vaccines available in India, Covaxin and Covishield We performed quantitative analysis of neutralizing antibodies to SARS Cov2 spike (receptor binding domain ) protein, from sera of 53 subjects who completed vaccines schedules. There was significantly higher immunogenic response with Covishield as compared to Covaxin and are independent of age. Studies on a large scale with long term follow up are needed to further advance the knowledge in this domain. Ever since SARS-CoV-2 spread globally, since 2019,there have been herculean efforts by many countries to produce effective vaccines against the organism. WHO collaborated on these efforts in the name of COVAX for global equitable access to COVID 19 Vaccines 1 CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted September 5, 2021. ; https://doi.org/10.1101/2021.08.28.21262753 doi: medRxiv preprint against SARS-CoV-2 ariants against delta variants. All these studies were done in different backgrounds of populations and there were no head to head trials comparing either their efficacy or effectiveness against emerging variants. While most of the studies were conducted as part of the vaccine trials, there is a paucity of information on how the responses were comparable between the two vaccines.In many studies titres of IgG is regarded as protective immunity against the virus 4,5 . Such information would facilitate improving immunoprophylactic strategies for SARSCoV2. With this background, we sought to compare the protective efficacy of Covaxin® and Covishield® vaccines through quantitative analysis of antibody titres response at least 10 days (Range 10 -90 days) after completing the full schedule. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 5, 2021. ; https://doi.org/10.1101/2021.08.28.21262753 doi: medRxiv preprint Ig G titers > 250 for the two vaccines are different (Covishield® produced a more immunogenic response compared to Covaxin®). Also we employed two sample t-test for estimating means of IgG titers of respective vaccines. For Covaxin® it was 23.7 ± 50.05 and for Covishield® it was 126 ± 149 .p value was 0.04 ( p < 0.05 being statistically significant). suggesting there is a significant difference in mean IgG values. Present study highlights preliminary findings on the variable efficacy of the two widely used SARS-CoV-2 vaccines in India 6 As it is already known the vaccine trials of Covishield® have been completed before its use for community vaccination, while the Covaxin® has been put into use much before the full results of the clinical trials are published in peer reviewed journals. Both of course were mentioned for emergency use meaning that the manufacturers would continue to improve the product for its best purpose. However, given that both the vaccines are being used widely across India, it is . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 5, 2021. ; logical to know how these two vaccines are performing in the real world, as compared to their efficacy during the trials. The trials were mostly based on measuring the protection against natural infection since it will not be possible to wait for months to measure the antibody titre. In this scenario it is logical to generate data on immunogenicity of each of these vaccines in order to understand their behaviour and predict the protective efficacy vis a vis the prevailing SARS-CoV-2 variants. This study attempted bringing out such information on a pilot basis. We found that IgG titres were significantly greater with Covisheld ®compared to Covaxin®. Effects of age, gender,duration of post vaccination for the initial three months are not significant . . Our pilot findings suggest greater immunogenicity of Covishield® compared to Covaxin ®while warranting further studies with large representative samples across the country which may further include other vaccines such as Sputnik® as well. ) 2. COVAXIN® -India's First Indigenous COVID-19 Vaccine ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant) COVISHIELDTM. Available online at Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection Antibody titers against SARS-CoV-2 decline, but do not disappear for several months Antibody Response after Second-dose of ChAdOx1-nCOV (Covishield™®) and BBV-152 (Covaxin™®) among Health Care Workers in India: Final Results of Cross-sectional Coronavirus Vaccine-induced Antibody Titre (COVAT) study Safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a, double-blind, randomised, controlled phase3trial.medRxiv2021.06.30.21259439 Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness